These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30801965)

  • 41. Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay.
    Langsdorf EF; Malikzay A; Lamarr WA; Daubaras D; Kravec C; Zhang R; Hart R; Monsma F; Black T; Ozbal CC; Miesel L; Lunn CA
    J Biomol Screen; 2010 Jan; 15(1):52-61. PubMed ID: 20019290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.
    McClerren AL; Endsley S; Bowman JL; Andersen NH; Guan Z; Rudolph J; Raetz CR
    Biochemistry; 2005 Dec; 44(50):16574-83. PubMed ID: 16342948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
    Piizzi G; Parker DT; Peng Y; Dobler M; Patnaik A; Wattanasin S; Liu E; Lenoir F; Nunez J; Kerrigan J; McKenney D; Osborne C; Yu D; Lanieri L; Bojkovic J; Dzink-Fox J; Lilly MD; Sprague ER; Lu Y; Wang H; Ranjitkar S; Xie L; Wang B; Glick M; Hamann LG; Tommasi R; Yang X; Dean CR
    J Med Chem; 2017 Jun; 60(12):5002-5014. PubMed ID: 28549219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.
    Erwin AL
    Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27235477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
    Surivet JP; Panchaud P; Specklin JL; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Lange R; Tidten-Luksch N; Gnerre C; Seeland S; Herrmann C; Seiler P; Enderlin-Paput M; Mac Sweeney A; Wicki M; Hubschwerlen C; Ritz D; Rueedi G
    J Med Chem; 2020 Jan; 63(1):66-87. PubMed ID: 31804826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety.
    Cohen F; Aggen JB; Andrews LD; Assar Z; Boggs J; Choi T; Dozzo P; Easterday AN; Haglund CM; Hildebrandt DJ; Holt MC; Joly K; Jubb A; Kamal Z; Kane TR; Konradi AW; Krause KM; Linsell MS; Machajewski TD; Miroshnikova O; Moser HE; Nieto V; Phan T; Plato C; Serio AW; Seroogy J; Shakhmin A; Stein AJ; Sun AD; Sviridov S; Wang Z; Wlasichuk K; Yang W; Zhou X; Zhu H; Cirz RT
    ChemMedChem; 2019 Aug; 14(16):1560-1572. PubMed ID: 31283109
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC.
    Kline T; Andersen NH; Harwood EA; Bowman J; Malanda A; Endsley S; Erwin AL; Doyle M; Fong S; Harris AL; Mendelsohn B; Mdluli K; Raetz CR; Stover CK; Witte PR; Yabannavar A; Zhu S
    J Med Chem; 2002 Jul; 45(14):3112-29. PubMed ID: 12086497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Common and varied molecular responses of Escherichia coli to five different inhibitors of the lipopolysaccharide biosynthetic enzyme LpxC.
    Möller AM; Vázquez-Hernández M; Kutscher B; Brysch R; Brückner S; Marino EC; Kleetz J; Senges CHR; Schäkermann S; Bandow JE; Narberhaus F
    J Biol Chem; 2024 Apr; 300(4):107143. PubMed ID: 38458396
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Escherichia coli versus Pseudomonas aeruginosa deacetylase LpxC inhibitors selectivity: surface and cavity-depth-based analysis.
    Kadam RU; Shivange AV; Roy N
    J Chem Inf Model; 2007; 47(3):1215-24. PubMed ID: 17441707
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
    Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor.
    Coggins BE; Li X; McClerren AL; Hindsgaul O; Raetz CR; Zhou P
    Nat Struct Biol; 2003 Aug; 10(8):645-51. PubMed ID: 12833153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition and structure-activity studies of methionine hydroxamic acid derivatives with bacterial peptide deformylase.
    Grant SK; Green BG; Kozarich JW
    Bioorg Chem; 2001 Aug; 29(4):211-22. PubMed ID: 16256693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, organocatalytic synthesis, and bioactivity evaluation of enantiopure fluorinated LpxC inhibitors.
    Rodríguez-Alvarado M; Russo R; Connell ND; Brenner-Moyer SE
    Org Biomol Chem; 2020 Aug; 18(30):5867-5878. PubMed ID: 32671374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
    Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
    Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An explorative study on potent Gram-negative specific LpxC inhibitors: CoMFA, CoMSIA, HQSAR and molecular docking.
    Shiri F; Salahinejad M; Dijoor R; Nejati-Yazdinejad M
    J Recept Signal Transduct Res; 2018 Apr; 38(2):151-165. PubMed ID: 29623756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 3-Aryl-4-acyloxyethoxyfuran-2(5H)-ones as inhibitors of tyrosyl-tRNA synthetase: synthesis, molecular docking and antibacterial evaluation.
    Wang XD; Deng RC; Dong JJ; Peng ZY; Gao XM; Li ST; Lin WQ; Lu CL; Xiao ZP; Zhu HL
    Bioorg Med Chem; 2013 Sep; 21(17):4914-22. PubMed ID: 23891164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Crystal structure of A. aeolicus LpxC with bound product suggests alternate deacetylation mechanism.
    Miller MD; Gao N; Ross PL; Olivier NB
    Proteins; 2015 Sep; 83(9):1706-19. PubMed ID: 26177919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
    Gao N; McLeod SM; Hajec L; Olivier NB; Lahiri SD; Bryan Prince D; Thresher J; Ross PL; Whiteaker JD; Doig P; Li AH; Hill PJ; Cornebise M; Reck F; Hale MR
    Protein Expr Purif; 2014 Dec; 104():57-64. PubMed ID: 25240855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polysaccharide deacetylases serve as new targets for the design of inhibitors against Bacillus anthracis and Bacillus cereus.
    Balomenou S; Koutsioulis D; Tomatsidou A; Tzanodaskalaki M; Petratos K; Bouriotis V
    Bioorg Med Chem; 2018 Jul; 26(13):3845-3851. PubMed ID: 29983281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of Escherichia coli UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase by Fe2+ yields a more efficient enzyme with altered ligand affinity.
    Hernick M; Gattis SG; Penner-Hahn JE; Fierke CA
    Biochemistry; 2010 Mar; 49(10):2246-55. PubMed ID: 20136146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.